The 3’UTR protects bone against menopause-induced osteoporosis via regulating CHD9 expression
Abstract
Osteoporosis is characterized by low bone mass, increased bone fragility, and elevated fracture susceptibility, with approximately one-third of postmenopausal women affected by this disease. Estrogen deficiency induces aberrant upregulation of microRNA (miRNA) expression, and the 3’-untranslated region (3’UTR) of mRNAs can bind to and sequester target miRNAs. This study aimed to identify target genes capable of sequestering and inhibiting miRNAs in postmenopausal osteoporosis (PMOP). Candidate differentially expressed microRNAs were screened by analyzing sequencing data from the whole blood and serum of PMOP patients. These candidate microRNAs were validated in the serum of PMOP patients, the serum and bone tissue of ovariectomized (OVX) mice, as well as in mouse osteoblasts and osteoclasts. Luciferase reporter assays were performed to verify the binding sites between the candidate microRNAs and their predicted target genes; argonaute 2 RNA immunoprecipitation (AGO2-RIP) assays were carried out to detect ceRNA binding at the cellular level, and in vivo therapeutic animal experiments were also implemented. We screened and cross-validated miR-144-5p and miR-532-5p, which were found to be highly expressed in the serum of PMOP patients, the serum and bone tissue of OVX mice, and mouse osteoblasts. The common target gene of these two miRNAs is chromodomain helicase DNA-binding protein 9 ( CHD9 ). Luciferase reporter assays confirmed that the p233-239 and p721-727 regions within the CHD9 3’UTR are the specific binding sites for miR-144-5p and miR-532-5p, respectively. In osteoblasts, CHD9 positively regulates the expression of runt-related transcription factor 2 ( RUNX2 ) by binding to the − 450 to -400 region of the RUNX2 promoter. In vivo experiments further demonstrated that the CHD9 3’UTR ameliorates ovariectomy-induced osteoporotic phenotypes. This study demonstrates that the CHD9 3’UTR offers a potential therapeutic strategy for postmenopausal osteoporosis.
Related
- Ischemic Postconditioning Protects Aged Myocardium Against Ischemia/Reperfusion Injury by Regulating Mitochondrial Dynamics via piR-4913.
- Ursolic Acid in Hippophae rhamnoides L. Protects against Alcohol-Induced Hepatic Injury by Alleviating Inflammatory Response and Regulating Fas/FasL Activation
- Atractylenolide Ⅲ protects granulosa cells from oxidative injury by regulating the NOX2/NRF2 axis in polycystic ovary syndrome
- SGLT2i protects against myocardial I/R-induced coronary microvascular injury by inhibiting glycocalyx degradation
- Perioperative sophocarpine protects against testicular ischemia/reperfusion injury by blocking JNK/p38 signaling
BibTeX
@article{zhang20263utr,
title = {{The 3’UTR protects bone against menopause-induced osteoporosis via regulating CHD9 expression}},
author = {Yang Zhang and Shasha Huang and Zhenpeng Guo and Xiaopeng Guo and Tianyu Shen and Hui Shang},
journal = {Scientific Reports},
year = {2026},
month = oct,
doi = {10.1038/s41598-026-76413-z},
url = {https://www.nature.com/articles/s41598-026-76413-z},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - The 3’UTR protects bone against menopause-induced osteoporosis via regulating CHD9 expression
AU - Yang Zhang
AU - Shasha Huang
AU - Zhenpeng Guo
AU - Xiaopeng Guo
AU - Tianyu Shen
AU - Hui Shang
PY - 2026
DA - 2026/10/26
JO - Scientific Reports
DO - 10.1038/s41598-026-76413-z
UR - https://www.nature.com/articles/s41598-026-76413-z
AB - Osteoporosis is characterized by low bone mass, increased bone fragility, and elevated fracture susceptibility, with approximately one-third of postmenopausal women affected by this disease. Estrogen deficiency induces aberrant upregulation of microRNA (miRNA) expression, and the 3’-untranslated region (3’UTR) of mRNAs can bind to and sequester target miRNAs. This study aimed to identify target genes capable of sequestering and inhibiting miRNAs in postmenopausal osteoporosis (PMOP). Candidate differentially expressed microRNAs were screened by analyzing sequencing data from the whole blood and serum of PMOP patients. These candidate microRNAs were validated in the serum of PMOP patients, the serum and bone tissue of ovariectomized (OVX) mice, as well as in mouse osteoblasts and osteoclasts. Luciferase reporter assays were performed to verify the binding sites between the candidate microRNAs and their predicted target genes; argonaute 2 RNA immunoprecipitation (AGO2-RIP) assays were carried out to detect ceRNA binding at the cellular level, and in vivo therapeutic animal experiments were also implemented. We screened and cross-validated miR-144-5p and miR-532-5p, which were found to be highly expressed in the serum of PMOP patients, the serum and bone tissue of OVX mice, and mouse osteoblasts. The common target gene of these two miRNAs is chromodomain helicase DNA-binding protein 9 ( CHD9 ). Luciferase reporter assays confirmed that the p233-239 and p721-727 regions within the CHD9 3’UTR are the specific binding sites for miR-144-5p and miR-532-5p, respectively. In osteoblasts, CHD9 positively regulates the expression of runt-related transcription factor 2 ( RUNX2 ) by binding to the − 450 to -400 region of the RUNX2 promoter. In vivo experiments further demonstrated that the CHD9 3’UTR ameliorates ovariectomy-induced osteoporotic phenotypes. This study demonstrates that the CHD9 3’UTR offers a potential therapeutic strategy for postmenopausal osteoporosis.
SN - 2045-2322
ER -